Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
International Journal of Diabetes in Developing Countries
Published in: International Journal of Diabetes in Developing Countries 3/2016

01-09-2016 | Review Article

Glycemic targets in diabetes

Authors: Hemraj B. Chandalia, Puja M. Thadani

Published in: International Journal of Diabetes in Developing Countries | Issue 3/2016

Login to get access

Abstract

Target setting is an important strategy in diabetes. The commonly used glycemic targets are blood glucose and HbA1c. The target values can be fixed based upon normative data or outcome data. Individualization of glycemic targets is based upon age of patient, duration of diabetes, life expectancy, type of diabetes, type of therapy, presence of complications, propensity for hypoglycemia, hypoglycemia awareness, availability of family support, patient motivation, and patient education. Currently, the rate of attainment of glycemic target is improving, and almost 50 % of diabetics achieve HbA1C targets. In pregnancy, glycemic targets recommended are strict. Furthermore, the concept of individualization needs to be extended to the pregnant state. We propose that the glycemic targets in pregnancy with diabetes should be different in gestational diabetes, pre-gestational type 2 diabetes, and type 1 diabetes.
Literature
1.
Mikesh LM, Bruns DE. Stabilization of glucose in blood specimens: mechanism of delay in fluoride inhibition of glycolysis. Clin Chem. 2008;54:930–2.CrossRefPubMed
2.
3.
Chandalia HB, Krishnaswamy PR. Glycated hemoglobin. Curr Sci. 2002;83:1522–32.
4.
Chandalia HB. Standardization of hemoglobin A1c. Int J Diab Dev Ctries. 2010;30:109–10.CrossRef
5.
Rohlfing C, Wiedmeyer HM, Little R, et al. Biological variation of glycohemoglobin. Clin Chem. 2002;48:1116–8.PubMed
6.
Selvin E, Crainiceanu CM, Brancati FL, Coresh J. Short-term variability in measures of glycemia and implications for the classification of diabetes. Arch Intern Med. 2007;167:1545–51.CrossRefPubMed
7.
International HbA1c Consensus Committee. Consensus statement on the worldwide standardization of the hemoglobin A1c measurement. Diabetes Care. 2010;33:1903–4.CrossRef
8.
Oliver NS, Toumazou C, Cass AEG, Johnston DG. Glucose sensors: a review of current and emerging technology. Diabet Med. 2009;26:197–210.CrossRefPubMed
9.
Hill NR, Oliver NS, Choudhary P, Levy JC, Hindmarsh P, Matthews DR. Normal reference range for mean tissue glucose and glycemic variability derived from continuous glucose monitoring for subjects without diabetes in different ethnic groups. Diabetes Technol Ther. 2011;13:921–8.CrossRefPubMedPubMedCentral
10.
Monnier L, Mas E, Ginet C, Michel F, Villon L, Cristol JP, Colette C. Activation of oxidative stress by acute glucose fluctuations compared with sustained chronic hyperglycemia in patients with type 2 diabetes. JAMA. 2006;295:1681–7.
11.
Strowig SM, Raskin P. Improved glycemic control in intensively treated type 1 diabetic patients using blood glucose meters with storage capability and computer-assisted analyses. Diabetes Care. 1998;21:1694–8.CrossRefPubMed
12.
Karter AJ, Ackerson LM, Darbinian JA, D’Agostino Jr RB, Ferrara A, Liu J, Selby JV. Self-monitoring of blood glucose levels and glycemic control: the Northern California Kaiser Permanente Diabetes registry. Am J Med. 2001;111:1–9.CrossRefPubMed
13.
Skyler JS. Diabetic complications: the importance of glucose control. Endocrinol Metab Clin N Am. 1996;25:243–54.CrossRef
14.
Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329:977–86.CrossRef
15.
Colagiuri S, Lee CM, Wong TY, et al. Glycemic thresholds for diabetes-specific retinopathy: implications for diagnostic criteria for diabetes. Diabetes Care. 2011;34:145–50.CrossRefPubMed
16.
Ramlo-Halsted BA, Edelman SV. The natural history of type 2 diabetes: practical points to consider in developing prevention and treatment strategies. Clinical Diabetes. 2000;18:80–4.
17.
Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy. N Engl J Med. 2000;342:381–9.CrossRef
18.
The Diabetes Control and Complications Trials/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study Research Group. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med. 2005;353:2643–53.CrossRef
19.
Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HAW. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008;359:1577–89.CrossRefPubMed
20.
UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352:837–53.CrossRef
21.
American Diabetes Association. Standards of medical care for patients with diabetes mellitus. Diabetes Care. 2002;25:S33–49.CrossRef
22.
Chandalia HB. Controversial question: how closely is it possible to treat type 2 diabetic patients to recommended therapeutic goals in daily clinical practice? Medicographia. 2002;24:46.
23.
Nathan DM, Buse JB, Davidson MB, et al. The American Diabetes Association; European Association for Study of Diabetes. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for Study of Diabetes. Diabetes Care. 2009;32:193–203.CrossRefPubMedPubMedCentral
24.
Handelsman Y, Bloomgarden ZT, Grunberger G, et al. American Association of Clinical Endocrinologists and American College of Endocrinology—clinical practice guidelines for developing a diabetes mellitus comprehensive care plan. Endocr Pract. 2015;21(suppl 1):1–87.CrossRefPubMedPubMedCentral
25.
IDF Clinical Guidelines Task Force. Global guideline for type 2 diabetes. International Diabetes Federation 2012, Brussels
26.
Canadian Diabetes Association Clinical Practice Guidelines Expert Committee. Canadian Diabetes Association 2013 clinical practice guidelines for the prevention and management of diabetes in Canada. Can J Diabetes. 2013;37(suppl 1):S1–S212.
27.
National Institute for Health and Care Excellence (NICE). Type 2 diabetes in adults: management. 2015. No: NG28
28.
ADVANCE Collaborative Group, Patel A, MacMohan S, Chalmers J, Neal B, Billot L, Woodward M, Marre M, Cooper M, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008;358:2560–72.CrossRef
29.
Action to Control Cardiovascular Risk in Diabetes Study Group, Gerstein HC, Miller ME, Byington RP, Buse JB, Cushman WC, et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008;358:2545-2559
30.
Duckworth W, Abraira C, Moritz T, Reda D, Emannele N, Reaven PD, Zieve FJ, Marks J, et al. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med. 2009;360:129–39.CrossRefPubMed
31.
Skyler JS, Bergenstal R, Bonow RO, Buse J, Deedwania P, Howard BV, Kirkman MS, Kosiborod M, et al. Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE and VA Diabetes Trials. Diabetes Care. 2009;32:187–92.CrossRefPubMedPubMedCentral
32.
Vijan S, Hofer T, Hayward R. Estimate benefits of glycemic control in microvascular complications in type 2 diabetes. Ann Intern Med. 1997;127:788–95.CrossRefPubMed
33.
Bethel M, Sloan F, Belsky D, et al. Longitudinal incidence and prevalence of adverse outcomes of diabetes mellitus in elderly patients. Arch Intern Med. 2007;167:921–7.CrossRefPubMed
34.
Davis A, Haller MJ, Miller K, et al. Residual C-peptide in patients 3-81 years from diagnosis of T1D: a T1D exchange study. Diabetes. 2013;62:A422.
35.
Heinemann L, Weyer C, Rauhaus M, Heinrichs S, Heise T. Variability of the metabolic effect of soluble insulin and the rapid acting insulin analogue insulin aspart. Diabetes Care. 1998;21:1910–4.CrossRefPubMed
36.
Heise T, Nosek L, Ronn BB, et al. Lower within-subject variability of insulin detemir in comparison to NPH insulin and insulin glargine in people with type 1 diabetes. Diabetes. 2004;53:1614–20.CrossRefPubMed
37.
Donnelly LA, Morris AD, Frier BM, Ellis JD, Donnan PT, Durrant R, Band MM, Reekie G, Leese P. Frequency and predictors of hypoglycemia in type 1 and insulin-treated type 2 diabetes: a population-based study. Diabet Med. 2005;22:749–55.CrossRefPubMed
38.
Turner RC, Cull CA, Frighi V, Holman RR. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). JAMA. 1999;281:2005–12.CrossRefPubMed
39.
40.
Heinemann L, Nosek L, Kapitza C, Schweitzer MA, Krinelke L. Changes in basal insulin infusion rates with subcutaneous insulin infusion. Diabetes Care. 2009;32:1437–9.CrossRefPubMedPubMedCentral
41.
Huang Z, Wan X, Liu J, Deng W, Chen A, Liu L, Liu J, Wei G, Li H, Fang D, Li Y. Short-term continuous subcutaneous insulin infusion combined with insulin sensitizers rosiglitazone, metformin or antioxidant alpha-lipoic acid in patients with newly diagnosed type 2 diabetes mellitus. Diabetes Technol Ther. 2013;15:859–69.CrossRefPubMedPubMedCentral
42.
Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M, et al. Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2012;35:1364–79.CrossRefPubMedPubMedCentral
43.
The DCCT Research Group. Adverse events and their association with treatment regimens in the diabetes control and complications trial. Diabetes Care. 1995;18:1415–27.CrossRef
44.
Cryer PE. Hypoglycaemia: the limiting factor in the glycaemic management of type I and type II diabetes. Diabetologia. 2002;45:937–48.CrossRefPubMed
45.
Chelliah YR. Ventricular arrhythmias associated with hypoglycaemia. Anaesth Intensive Care. 2000;28:698–700.PubMed
46.
47.
Adler GK, Bonyhay I, Failing H, Waring E, Dotson S, Freeman R. Antecedent hypoglycemia impairs autonomic cardiovascular function: implications for rigorous glycemic control. Diabetes. 2009;58:360–6.CrossRefPubMedPubMedCentral
48.
Norris SL, Lau J, Smith SJ, Schmid CH, Engelgau MM. Self-management education for adults with type 2 diabetes: a meta-analysis of the effect on glycemic control. Diabetes Care. 2002;25:1159–71.CrossRefPubMed
49.
Williams MV, Baker DW, Parker RM, et al. Relationship of functional health literacy to patients’ knowledge of their chronic disease. A study of patients with hypertension and diabetes. Arch Int Med. 1998;158(2):166–72.CrossRef
50.
Schillinger D, Grumbach K, Piette J, et al. Association of health literacy with diabetes outcomes. J Am Med Assoc. 2002;288:475–82.CrossRef
51.
Hoerger TJ, Segel JE, Gregg EW, Saaddine JB. Is glycemic control improving in U.S. Adults? Diabetes Care. 2008;31:81–6.CrossRefPubMed
52.
Blumenthal KJ, Larkin ME, Winning G, Nathan DM, Grant RW. Changes in glycemic control from 1996 to 2006 among adults with type 2 diabetes: a longitudinal cohort study. BMC Health Serv Res. 2010;10:158.CrossRefPubMedPubMedCentral
53.
Monnier L, Lapinski H, Colette C. Contributions of fasting and post-prandial plasma glucose increments to the overall diurnal hyperglycaemia of type 2 diabetic patients: variations with increasing levels of HbA1c. Diabetes Care. 2003;26:881–5.CrossRefPubMed
54.
Monnier L, Colette C, Dunseath GJ. The loss of postprandial glycaemic control precedes stepwise deterioration of fasting with worsening diabetes. Diabetes Care. 2007;30:263–9.CrossRefPubMed
55.
Riddle M, Umpierrez G, DiGenio A, Zhou R, Rosenstock J. Contributions of basal and postprandial hyperglycemia over a wide range of A1C levels before and after treatment intensification in type 2 diabetes. Diabetes Care. 2011;34:2508–14.CrossRefPubMedPubMedCentral
56.
57.
58.
Hernandez TL, Friedman JE, van Pelt RE, Barbour LA. Patterns of glycemia in normal pregnancy: should the current therapeutic targets be challenged. Diabetes Care. 2011;34:1660–8.CrossRefPubMedPubMedCentral
59.
O’Connor C, O’Shea PM, Owens LA, et al. Trimester-specific reference intervals for hemoglobin A1c (HbA1c) in pregnancy. Clin Chem Lab Med. 2011;50:905–9.PubMed
60.
Blumer I, Hadar E, Hadden DR, Jovanovic L, Mestman JH, Murad MH, et al. Diabetes and pregnancy: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2013;98:4227–49.CrossRefPubMed
61.
Thompson D, Berger H, Feig D, Gagnon R, Kader T, Keely E, et al. Diabetes and pregnancy. Can J Diabetes. 2013;37Suppl 1: S168–83
62.
National Institute for Health and Care Excellence (NICE). Diabetes in pregnancy: management of diabetes and its complications from pre-conception to the postnatal period. 2008. Report 97. No.: CG63
63.
American Diabetes Association. Standards of medical care in diabetes–2015. Diabetes Care 2015;38Suppl 1:S77-S79
64.
Cheung NW, Conn JJ, d’Emden MC, Gunton JE, Jenkins AJ, Ross GP, et al. Position statement of the Australian Diabetes Society: individualization of glycatedhemoglobin targets for adults with diabetes mellitus. Med J Aust. 2009;191:339–44.PubMed
65.
Suhonen L, Hiilesmaa V, Teramo K. Glycemic control during early pregnancy and fetal malformations in women with type 1 diabetes mellitus. Diabetologia. 2000;43:79–82.CrossRefPubMed
66.
Guerin A, Nisenbaum R, Ray JG. Use of maternal GHb concentration to estimate the risk of congenital anomalies in the offspring of women with pre-pregnancy diabetes. Diabetes Care. 2007;30:1920–5.CrossRefPubMed
67.
Jensen DM, Korsholm R, Ovesen P, et al. Peri-conceptional A1c and risk of serious adverse pregnancy outcome in 933 women with type 1 diabetes. Diabetes Care. 2009;32:1046–8.CrossRefPubMedPubMedCentral
68.
Greene MF, Hare JW, Cloherty JP, Benacerraf BR, Soeldner JS. First trimester hemoglobin A1 and risk for major malformation and spontaneous abortion in diabetic pregnancy. Teratology. 1989;39:225–31.CrossRefPubMed
69.
Miodovnik M, Mimouni F, Tsang RC, Ammar E, Kaplan L, Siddiqi TA. Glycemic control and spontaneous abortion in insulin-dependent diabetic women. ObstetGynecol. 1986;68:366–9.
70.
Mills JL, Simpson JL, Driscoll SG, Jovanovic-Peterson L, Van Allen M, Aarons JH, Metzger B, et al. Incidence of spontaneous abortion among normal women and insulin-dependent diabetic women whose pregnancies were identified within 21 days of conception. N Engl J Med. 1988;319:1617–23.CrossRefPubMed
71.
Jovanovic L, Knopp RH, Kim H, Cefalu WT, Simpson JL, Mills JL, et al. Elevated pregnancy losses at high and low extremes of maternal glucose in early normal and diabetic pregnancy. Diabetes Care. 2005;28:1113–7.CrossRefPubMed
72.
Damm P, Mersebach H, Rastam J, Kaaja R, et al. Poor pregnancy outcome in women with type 1 diabetes is predicted by elevated HbA1c and spikes of high glucose values in the third trimester. J Matern Fetal Neonatal Med. 2014;27:149–54.CrossRefPubMed
73.
Mello G, Parretti E, Mecacci F, La TP, Cioni R, Cianciulli D, et al. What degree of maternal metabolic control in women with type 1 diabetes is associated with normal body size and proportions in full-term infants? Diabetes Care. 2000;23:1494–8.CrossRefPubMed
74.
Combs CA, Gunderson E, Kitzmiller JL, Gavin LA, Main EK. Relationship of fetal macrosomia to maternal postprandial glucose control during pregnancy. Diabetes Care. 1992;15:1251–7.CrossRefPubMed
75.
Lind T, Cheyne GA. Effect of normal pregnancy upon the glycosylated hemoglobins. Br J Obstet Gynaecol. 1979;86:210–3.CrossRefPubMed
76.
Lurie S Age distribution of erythrocyte population in late pregnancy. Gynecol Obstet Investig. 1990;30:147–9.CrossRef
77.
Lurie S, Danon D. Life span of erythrocytes in late pregnancy. Obstet Gynecol. 1992;80:123–6.PubMed
78.
Lurie S, Mamet Y. Red blood cell survival and kinetics during pregnancy. Eur J Obstet Gynecol Reprod Biol. 2000;93:185–92.CrossRefPubMed
79.
Evers IM, de Valk HW, Visser GHA. Risk of complications of pregnancy in women with type 1 diabetes: nationwide prospective study in the Netherlands. Br Med J. 2004;328:915–8.CrossRef
80.
Jensen DM, Damm P, Moelsted-Pedersen L, et al. Outcomes in type 1 diabetic pregnancies: a nationwide, population-based study. Diabetes Care. 2004;27:2819–23.CrossRefPubMed
81.
Clausen TD, Mathiesen E, Ekbom P, Hellmuth E, Mandrup-Poulsen T, Damm P. Poor pregnancy outcome in women with type 2 diabetes. Diabetes Care. 2005;28:323–8.CrossRefPubMed
82.
Huddle KR. Audit of the outcome of pregnancy in diabetic women in Soweto, South Africa, 1992–2002. S Afr Med J. 2005;95:789–94.PubMed
83.
Roland JM, Murphy HR, Ball V, Northcote-Wright J, Temple RC. The pregnancies of women with type 2 diabetes: poor outcomes but opportunities for improvement. Diabet Med. 2005;22:1774–7.CrossRefPubMed
84.
Hillman Gadea N, Herranz L, Vaquero PM, Villarroel A, Fernandez A, Pallardo LF. Is pregnancy outcome worse in type 2 than in type 1 diabetic women? Diabetes Care. 2006;29:2557–8.CrossRef
85.
Gimenez M, Conget I, Nicolau J, Pericot A, Levy I. Outcome of pregnancy in women with type 1 diabetes intensively treated with continuous subcutaneous insulin infusion or conventional therapy. A case-control study. Acta Diabetol. 2007;44:34–7.CrossRefPubMed
86.
Gonzalez-Gonzalez NL, Ramirez O, Mozas J, et al. Factors influencing pregnancy outcome in women with type 2 versus type 1 diabetes mellitus. Acta Obstetriciaet Gynecologica Scandinavica. 2008;87:43–9.CrossRef
87.
Murphy HR, Steel SA, Roland JM, et al. Obstetric and perinatal outcomes in pregnancies complicated by type1 and type2 diabetes: influences of glycaemic control, obesity and social disadvantage. Diabet Med. 2011;28:1060–7.CrossRefPubMedPubMedCentral
88.
89.
deValk HW, van Nieuwaal NH, Visser GH. Pregnancy outcome in type 2 diabetes mellitus: a retrospective analysis from the Netherlands. The Review of Diabetic Studies. 2006;3:134–42.CrossRef
90.
Langer O, Conway DL, Berkus MD, Gonzales O, et al. A comparison of glyburide and insulin in women with gestational diabetes mellitus. N Engl J Med. 2000;343:1134–8.CrossRefPubMed
91.
Rowan JA, Hague WM, Gao W, Battin MR, Moore MP, et al. Metformin versus insulin for the treatment of gestational diabetes. N Engl J Med. 2008;358:2003–15.CrossRefPubMed
92.
Metzger BE, Lowe LP, Dyer AR, Trimble ER, et al. Hyperglycemia and adverse pregnancy outcomes. N Engl J Med. 2008;358:1991–2002.CrossRefPubMed
93.
Prutsky GJ, Domecq JP, Wang Z, Carranza Leon BG, Elraiyah T, Nabhan M, et al. Glucose targets in pregnant women with diabetes: a systematic review and meta-analysis. J Clin Endocrinol Metab. 2013;98:4319–24.CrossRefPubMed
Metadata
Title
Glycemic targets in diabetes
Authors
Hemraj B. Chandalia
Puja M. Thadani
Publication date
01-09-2016
Publisher
Springer India
Published in
International Journal of Diabetes in Developing Countries / Issue 3/2016
Print ISSN: 0973-3930
Electronic ISSN: 1998-3832
DOI
https://doi.org/10.1007/s13410-016-0467-8

Other articles of this Issue 3/2016

International Journal of Diabetes in Developing Countries 3/2016 Go to the issue

Original Article

Evaluation of foot care and self-efficacy in patients with diabetes in Turkey: an interventional study

Original Article

Assessment of multimedia-supported intervention in Muslim diabetic patients treated with insulin

Original Article

Association of sociodemographics, technology use and health literacy among type 2 diabetic individuals living in an Indian setting: an exploratory cross-sectional study

Letter to Editor

Impairment in glycemic control and lipid profile during the Indian festival of Diwali

Original Article

Health suggestibility, optimism and sense of responsibility for health in diabetic patients

Original Article

Prevalence and risk factors of metabolic syndrome among an endangered tribal population in Malaysia using harmonized IDF criteria
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits